Williams, Erik A.
Santagata, Sandro
Wakimoto, Hiroaki
Shankar, Ganesh M.
Barker, Fred G. II
Sharaf, Radwa
Reddy, Abhinav
Spear, Phoebe
Alexander, Brian M.
Ross, Jeffrey S.
Brastianos, Priscilla K.
Cahill, Daniel P.
Ramkissoon, Shakti H.
Juratli, Tareq A. http://orcid.org/0000-0003-2236-6719
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 22 September 2020
Accepted: 23 September 2020
First Online: 21 October 2020
Competing interests
: EAW, RS, AR, JMV, BMA, JSR, and SHR are employees or consultants of Foundation Medicine, Inc., a wholly owned subsidiary of Roche Holdings, Inc. and Roche Finance Ltd, and these employees have equity interest in an affiliate of these Roche entities. SS is a consultant for RareCyte. PKB reports honoraria for consulting from Tesaro, Lilly, Angiochem, and Genentech<b>-</b>Roche; speaker’s honoraria from Genentech<b>-</b>Roche and Merck; and research funding (to Massachusetts General Hospital) from BMS, Pfizer, Lilly and Merck. DPC reports receiving honoraria from Merck, Lilly and Boston Pharmaceuticals outside the submitted work. TAJ received honoraria from CSL Behring and Roche Pharma AG unrelated to the submitted work.